Results 71 to 80 of about 47,434 (363)

A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases. [PDF]

, 2017
A challenge in precision medicine requires identification of actionable driver mutations. Critical to such effort is the deployment of sensitive and well-validated assays for mutation detection.
Ali, Siraj, Bergsland, Emily K, Bivona, Trever G, Damato, Bertil, Fogh, Shannon, Miller, Vincent A, Urisman, Anatoly, Wang, Victoria E, Wolfe, John, Young, Lauren   +9 more
core   +1 more source

Expanding the clinical uses of ctDNA

Practical oncology, 2021
The majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal with the detection of mutations. The analysis of cfDNA is often discussed in the context of the noninvasive detection of mutations that lead to resistance mechanisms and therapeutic and disease monitoring in cancer patients.
openaire   +1 more source

Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses

Nature Network Boston
Gastroesophageal cancer dynamics and drivers of clinical responses with immune checkpoint inhibitors (ICI) remain poorly understood. Potential synergistic activity of dual programmed cell death protein 1 (PD-1) and lymphocyte-activation gene 3 (LAG-3 ...
R. Kelly, Blair V. Landon, A. Zaidi, Dipika Singh, Jenna V. Canzoniero, A. Balan, R. K. Hales, K. R. Voong, R. Battafarano, B. Jobe, Stephen C. Yang, Stephen Broderick, J. Ha, K. Marrone, Gavin Pereira, N. Rao, Aryan Borole, Katerina Karaindrou, Z. Belcaid, James R. White, Suqi Ke, A. I. Amjad, Benny Weksler, E. J. Shin, E. Thompson, Kellie N. Smith, Drew M Pardoll, Chen Hu, J. Feliciano, V. Anagnostou, V. Lam   +30 more
semanticscholar   +1 more source

Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond

British Journal of Cancer, 2020
Cell-free DNA (cfDNA) derived from tumours is present in the plasma of cancer patients. The majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal with the detection of mutations.
Laura Keller, Yassine Belloum, H. Wikman, K. Pantel   +3 more
semanticscholar   +1 more source

Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients

Clinical Cancer Research, 2023
Purpose: Prognostic and predictive biomarkers to cyclin-dependent kinases 4 and 6 inhibitors are lacking. Circulating tumor DNA (ctDNA) can be used to profile these patients and dynamic changes in ctDNA could be an early predictor of treatment efficacy ...
J. Pascual, M. Gil-Gil, P. Proszek, C. Zielinski, Alistair Reay, M. Ruíz-Borrego, R. Cutts, E. C. Ciruelos Gil, A. Feber, M. Muñoz-Mateu, C. Swift, B. Bermejo, J. Herranz, Mireia Margelí Vila, A. Antón, Z. Kahán, T. Csöszi, Yuan Liu, Daniel Fernandez Garcia, I. Garcia-Murillas, M. Hubank, N. Turner, Miguel Martín   +22 more
semanticscholar   +1 more source

Phylogenetic ctDNA analysis depicts early stage lung cancer evolution

Nature, 2017
The early detection of relapse following primary surgery for non-small-cell lung cancer and the characterization of emerging subclones, which seed metastatic sites, might offer new therapeutic approaches for limiting tumour recurrence.
C. Abbosh, Nicolai J. Birkbak, G. Wilson, M. Jamal-Hanjani, T. Constantin, R. Salari, J. Le Quesne, D. Moore, S. Veeriah, R. Rosenthal, T. Marafioti, E. Kırkızlar, T. Watkins, N. Mcgranahan, S. Ward, L. Martinson, Joan Riley, F. Fraioli, M. Al Bakir, E. Grönroos, F. Zambrana, R. Endozo, W. Bi, F. Fennessy, Nicole Sponer, Diana H. Johnson, J. Laycock, S. Shafi, J. Czyzewska-Khan, A. Rowan, T. Chambers, Nik Matthews, S. Turajlic, C. Hiley, S. Lee, M. Forster, T. Ahmad, M. Falzon, E. Borg, D. Lawrence, M. Hayward, S. Kolvekar, N. Panagiotopoulos, S. Janes, R. Thakrar, Asia Ahmed, F. Blackhall, Y. Summers, D. Hafez, A. Naik, Apratim Ganguly, S. Kareht, R. Shah, L. Joseph, A. Quinn, P. Crosbie, B. Naidu, G. Middleton, G. Langman, S. Trotter, M. Nicolson, H. Remmen, K. Kerr, M. Chetty, L. Gomersall, D. Fennell, A. Nakas, S. Rathinam, G. Anand, S. Khan, P. Russell, V. Ezhil, Babikir Ismail, Melanie Irvin-sellers, V. Prakash, J. Lester, M. Kornaszewska, R. Attanoos, Haydn Adams, H. Davies, D. Oukrif, A. Akarca, J. Hartley, H. Lowe, S. Lock, N. Iles, Harriet Bell, Y. Ngai, G. Elgar, Z. Szallasi, R. Schwarz, Javier Herrero, A. Stewart, S. Quezada, K. Peggs, P. Van Loo, C. Dive, Jimmy Lin, M. Rabinowitz, H. Aerts, A. Hackshaw, J. Shaw, B. Zimmermann, C. Swanton   +103 more
semanticscholar   +1 more source

Liquid biopsy genotyping in lung cancer: ready for clinical utility? [PDF]

, 2017
Liquid biopsy is a blood test that detects evidence of cancer cells or tumor DNA in the circulation. Despite complicated collection methods and the requirement for technique-dependent platforms, it has generated substantial interest due, in part, to its ...
Chen, Yi-Lin, Ho, Chung-Liang, Huang, Wei-Lun, Lin, Chien-Chung, Su, Wu-Chou, Wei, Fang, Wong, David T, Yang, Szu-Chun   +7 more
core   +1 more source

CTC, ctDNA, and Exosome in Thyroid Cancers: A Review

International Journal of Molecular Sciences, 2023
Thyroid cancer has become more common in recent years all around the world. Many issues still need to be urgently addressed in the diagnosis, treatment, and prognosis of thyroid cancer. Liquid biopsy (mainly circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and circulating exosomes) may provide a novel and ideal approach to solve these ...
Wang, Wenwen, Zheng, Zhiyao, Lei, Jianyong   +2 more
openaire   +2 more sources

Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial

BMC Medicine, 2023
Background There is increasing interest in the use of liquid biopsies, but data on longitudinal analyses of circulating tumor DNA (ctDNA) remain relatively limited.
J. Chiu, F. Su, Mukta Joshi, N. Masuda, Takashi Ishikawa, T. Aruga, J. P. Zarate, N. Babbar, O. A. Balbin, Y. Yap   +9 more
semanticscholar   +1 more source

Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC

Molecular Oncology, 2023
Brain metastasis (BM) genetically diverges from the primary tumor in non‐small‐cell lung cancer (NSCLC). Hence, accurately capturing clinically relevant alterations is pivotal for the delivery of targeted therapies.
Jun Wu, Zhiqiang Liu, Tianxiang Huang, Ying Wang, Meng Meng Song, Tao Song, Gretchen Long, Xiaobing Zhang, Xi Li, Longbo Zhang   +9 more
doaj   +1 more source